The well-established anti-muscarinic drug-class dominates the overactive bladder market and continued generic erosion of these agents will be the most significant constraint on future growth. However, for patients in whom these drugs are not effective, there are limited options. The two most recent market entrants, Astellas’s Myrbetiq and Allergan’s Botox (both of which offer alternative MOAs) have enjoyed strong growth in this market driven by a need for therapies effective in patients who are refractory to the anti-muscarinics, direct-to-consumer promotion, and life-cycle management strategies employed by their developers.
· What patient share do key therapies and brands garner by line of therapy in newly diagnosed overactive bladder patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed overactive patients?
· How have more recent market entrants such as Myrbetriq and Botox been integrated into the treatment algorithm?
· What proportion of overactive bladder patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
· What percentage of overactive bladder patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
· What are the product-level compliance and persistency rates among drug-treated patients with overactive bladder?